Monday, May 12, 2025
spot_img

27/2025・Trifork Group: Weekly report on share buyback

Company announcement no. 27 / 2025
Schindellegi, Switzerland – 12 May 2025


Trifork Group: Weekly report on share buyback

On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no. 7 of 28 February 2025.

Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share capital. Under the program, the following transactions have been made:

Date      Number of shares        Average purchase price (DKK)        Transaction value (DKK)
Total beginning 74,679 85.74 6,403,060
5 May 2025 1,500 90.12 135,180
6 May 2025 1,297 92.45 119,908
7 May 2025 1,700 91.34 155,278
8 May 2025 1,600 92.65 148,240
9 May 2025 1,398 92.27 128,993
Accumulated 82,174 86.29 7,090,659

A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/

Since the share buyback program was started on 4 March 2025, the total number of repurchased shares is 82,174 at a total amount of DKK 7,090,659. On 25 March and on 25 April 2025, 2,929 shares acquired through the share buyback program were utilized for the Executive Management’s monthly fixed salary, representing a change from cash payment to payment partly in shares (refer to company announcement no. 1 of 21 January 2025). On 1 April 2025, 19,943 shares acquired through the share buyback program were utilized to serve the RSU plan of Executive Management and certain employees.

With the transactions stated above, Trifork holds a total of 315,631 treasury shares, corresponding to 1.6%. The total number of registered shares in Trifork is 19,744,899. Adjusted for treasury shares, the number of outstanding shares is 19,429,268.


Investor and media contact
Frederik Svanholm, Group Investment Director, [email protected], +41 79 357 73 17

About Trifork
Trifork is a pioneering and global technology partner, empowering enterprise and public sector customers with innovative digital solutions. With 1,215 professionals across 71 business units in 16 countries, Trifork specializes in designing, building, and operating advanced software across sectors such as public administration, healthcare, manufacturing, logistics, energy, financial services, retail, and real estate. The Group’s R&D arm, Trifork Labs, drives innovation by investing in and developing synergistic, high-potential technology companies. Trifork Group AG is publicly listed on Nasdaq Copenhagen. Learn more at trifork.com.

 

 

Attachment

  • CA_27_25_Buyback

Powered by SlickText.com

Hot this week

Orbit International Corp. Reports 2025 First Quarter Results

First Quarter 2025 Net Loss of $2,152,000 ($0.65 loss...

Share buy-back program

COMPANY ANNOUNCEMENT NO 26/2025 - May 12, 2025 ...

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

Conference Call Scheduled for Thursday, May 15, 2025 at...

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Adds nine additional countries to the Company’s ongoing pivotal...

Barnes & Noble Education Announces Surge in New Campus Store Partnerships

Over 20 new institutions across a mix of two-...

Topics

Orbit International Corp. Reports 2025 First Quarter Results

First Quarter 2025 Net Loss of $2,152,000 ($0.65 loss...

Share buy-back program

COMPANY ANNOUNCEMENT NO 26/2025 - May 12, 2025 ...

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Adds nine additional countries to the Company’s ongoing pivotal...

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

Significant Neurological Expertise to Help Drive Clinical Development Strategy and...
spot_img

Related Articles

Popular Categories

spot_img